Frequency Therapeutics · Regenerative Medicine · Phase 2
DiscontinuedTherapeutic
Population
Adults · 18–65 years
Stable noise- or sudden-onset SNHL
Evidence
company
Confidence
96%
Indications
Hearing LossSensorineural Hearing LossNoise-Induced Hearing LossSudden Sensorineural Hearing Loss
